Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 known ✓ | P52333 | 4/20 | 0.54 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.51 |
| ▸ | BTK known ✓ | Q06187 | 2/20 | 0.50 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.50 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.50 |
| ▸ | RAF1 known ✓ | P04049 | 1/20 | 0.50 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.50 |
| ▸ | INSR known ✓ | P06213 | 1/20 | 0.50 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.50 |
| ▸ | IGF1R known ✓ | P08069 | 1/20 | 0.50 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.50 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.50 |
| ▸ | BRAF known ✓ | P15056 | 1/20 | 0.50 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.50 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.50 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.50 |
| ▸ | TEC known ✓ | P42680 | 1/20 | 0.50 |
| ▸ | TXK known ✓ | P42681 | 1/20 | 0.50 |
| ▸ | BMX known ✓ | P51813 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2103810 | 0.93 | ADORA3 (0.65) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL2104145 | 0.92 | SYK (0.62) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL2102411 | 0.92 | SYK (0.67) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL2103278 | 0.90 | SYK (0.69) | SYKADORA3TYRO3JAK1JAK3 | |
| Hydrochloric Acid SCHEMBL2100858 | 0.89 | SYK (0.68) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL2104246 | 0.87 | ADORA3 (0.62) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL2102858 | 0.86 | SYK (0.57) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL2105664 | 0.83 | SYK (0.73) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL2102163 | 0.83 | SYK (0.63) | SYKADORA3TYRO3JAK1JAK3 | |
| SCHEMBL3852709 | 0.82 | SYK (0.60) | SYKADORA3TYRO3JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120230984-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | claimed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | claimed |
| EP-2130541-A2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | Rigel Pharmaceuticals, Inc. (US) | 2009-12-09 | — | — | EP | claimed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120230984-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | JAK3 1034/4885EGFR 3376/4885BTK 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.